Interchange Capital Partners LLC Makes New $285,000 Investment in 10x Genomics, Inc. (NASDAQ:TXG)

Interchange Capital Partners LLC acquired a new position in 10x Genomics, Inc. (NASDAQ:TXG) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 12,623 shares of the company’s stock, valued at approximately $285,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Allspring Global Investments Holdings LLC raised its stake in 10x Genomics by 113.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 698 shares of the company’s stock worth $26,000 after purchasing an additional 371 shares in the last quarter. Covestor Ltd increased its holdings in 10x Genomics by 501.7% in the 1st quarter. Covestor Ltd now owns 1,047 shares of the company’s stock valued at $39,000 after buying an additional 873 shares during the period. GAMMA Investing LLC increased its holdings in 10x Genomics by 451.8% in the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock valued at $35,000 after buying an additional 1,265 shares during the period. Blue Trust Inc. increased its holdings in 10x Genomics by 136.5% in the 3rd quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock valued at $40,000 after buying an additional 1,025 shares during the period. Finally, Headlands Technologies LLC bought a new position in 10x Genomics in the 1st quarter valued at about $71,000. Institutional investors and hedge funds own 84.68% of the company’s stock.

Insider Activity at 10x Genomics

In related news, insider Benjamin J. Hindson sold 4,351 shares of the business’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total transaction of $98,028.03. Following the transaction, the insider now owns 345,704 shares in the company, valued at $7,788,711.12. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other 10x Genomics news, insider Benjamin J. Hindson sold 4,351 shares of the business’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total transaction of $98,028.03. Following the completion of the sale, the insider now owns 345,704 shares in the company, valued at approximately $7,788,711.12. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Serge Saxonov sold 6,749 shares of the business’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total transaction of $152,054.97. Following the sale, the chief executive officer now owns 882,467 shares of the company’s stock, valued at $19,881,981.51. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 14,061 shares of company stock worth $316,794 in the last quarter. Company insiders own 10.03% of the company’s stock.

10x Genomics Stock Performance

Shares of NASDAQ TXG opened at $16.33 on Friday. 10x Genomics, Inc. has a 52-week low of $14.02 and a 52-week high of $57.90. The company’s 50 day moving average price is $19.85 and its 200-day moving average price is $21.33.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings results on Tuesday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.04. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. The firm had revenue of $151.65 million for the quarter, compared to the consensus estimate of $158.84 million. During the same quarter in the previous year, the company earned ($0.51) EPS. The company’s revenue for the quarter was down 1.3% on a year-over-year basis. On average, analysts predict that 10x Genomics, Inc. will post -1.4 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on TXG. JPMorgan Chase & Co. decreased their target price on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday. Stifel Nicolaus decreased their target price on shares of 10x Genomics from $53.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, July 16th. Stephens reissued an “overweight” rating and issued a $30.00 target price on shares of 10x Genomics in a report on Thursday, October 10th. Barclays decreased their target price on shares of 10x Genomics from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Friday. Finally, Leerink Partnrs raised shares of 10x Genomics to a “strong-buy” rating in a report on Tuesday, September 3rd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $29.19.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.